Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Rituximab (MabThera) added to standard chemotherapy in untreated mantle cell lymphoma
2009-011433-27Phase 2Terminated
- Sponsor
- Roche
- Start
- Dec 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of rituximab in mantle cell lymphoma (MCL), sponsored by Roche. Primary endpoint: Overall Response Rate. Started Dec 2016; status: terminated.
02
Drugs
rituximab
03
Conditions
mantle cell lymphoma (MCL)
Beyond the preview
Go deeper on 2009-011433-27.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-011433-27.